Oramed Pharmaceuticals INC 8-K filings

Oramed Pharmaceuticals received early payments totaling $15 million on a promissory note from Scilex Holding Company, ahead of the scheduled March 21, 2024 payment date.

Oramed Pharmaceuticals has appointed Yehuda Reznick as a new director and chair of the audit committee, effective April 1, 2024.

Oramed Pharmaceuticals has entered into a new at-the-market offering agreement for up to $75 million in common stock and terminated a prior agreement with Cantor Fitzgerald.

Oramed is set to initiate a new Phase 3 oral insulin trial in the U.S. following positive subpopulation analysis and has formed a joint venture with HTIT, including a $90 million capital infusion.

Oramed Pharmaceuticals has formed a joint venture with Hefei Tianhui Biotech to develop and commercialize oral drug delivery products, including oral insulin, with a focus on a Phase 3 trial in the US.

Yadin Rozov resigned from the Oramed Pharmaceuticals Inc. Board of Directors effective immediately on January 17, 2024, citing personal reasons.